A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
In this video, renowned oncologist Dr. Joyce O’Shaughnessy speaks about how treatment outcomes may vary for patients with HR+, HER2- MBC depending on the breast cancer subtype and the underlying disease heterogeneity.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
Comments are disabled for this content.
